Key result
Adding atorvastatin to evolocumab reduces aortic intimal thickness ~24% more than evolocumab alone.
RCT (n=50)
Randomly assigned to five groups
Answers are grounded in this paper and cite their sources.
Demonstrates that evolocumab alone and with atorvastatin reduces atherosclerosis progression and inflammatory markers in rabbits, indicating vascular protective mechanisms.
Evolocumab, a PCSK-9 inhibitor, is known for its ability to reduce low-density lipoprotein cholesterol (LDL-C). This study aimed to investigate the effects of evolocumab, alone or in combination with atorvastatin, on the progression of atherosclerosis. Fifty male domestic rabbits were randomly assigned to five groups: control, high cholesterol diet, evolocumab vehicle (dimethyl sulfoxide, DMSO), evolocumab alone, and evolocumab plus atorvastatin. Serum levels of interleukin 10 (IL-10), IL-17, IL-1β, intracellular adhesion molecule (ICAM), and vascular adhesion molecule (VCAM) were measured. Toll-like receptor (TLR) expression on monocytes was evaluated using flow cytometry. Histopathological examination and measurement of intimal thickness (IT) were also conducted. The results revealed that the evolocumab produced a statistically significant (p<0.05) reduction in lipid profile at 5 weeks, with the peak effect occurring at 10 weeks. Furthermore, the inhibitor reduced TLRs at 10 weeks to 10.83±1.8 and intimal thickness to 160.66±9.45. IL-17, IL-1β, ICAM, and VCAM were significantly reduced by evolocumab treatment, with the improvement of the histopathological changes in the aortic wall. The combination of evolocumab and atorvastatin caused a more statistically significant reduction in TLRs at 10 weeks to 5.08±1.2 and intimal thickness to 121.79±5.3. IL-17, IL-1β, ICAM, and VCAM were significantly (p<0.05) reduced by the combination, and the histopathological changes in the aortic wall were significantly improved. In conclusion, evolocumab delays the progression of atherosclerosis by modulating inflammatory pathways.
No takes yet. Share an insight, caveat, or question.
Hadi et al. (2023) conducted an RCT in Atherosclerosis (n=50). Evolocumab alone and in combination with atorvastatin vs. Control, high cholesterol diet, or evolocumab vehicle (DMSO) was evaluated on Atherosclerosis progression (intimal thickness, lipid profile, TLR expression on monocytes, and inflammatory cytokines) (p=<0.05). Evolocumab plus atorvastatin reduced monocyte TLRs to 5.08±1.2 and aortic intimal thickness to 121.79±5.3 at 10 weeks compared to evolocumab alone.
Synapse has enriched 10 related papers. Consider them for comparative context: